A Phase 2 interventional study of Vonoprazan and Esomeprazole in Gastroesophageal Reflux, sponsored by Takeda. Completed at 39 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-18.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing esomeprazole in Gastroesophageal Reflux — 1 open to participants now, 1 under way, none of them phase 3. Esomeprazole · Gastroesophageal Reflux.
Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, this one is the 24th largest by enrollment of the 66 interventional ones that give a count, is the only one that started in 2016, is one of 5 in phase 2, and was the 57th registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →1 of the 67 studies testing esomeprazole in Gastroesophageal Reflux is open now, in 1 country. Recruiting first, the newest first:
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–75
By country, each count listing its studies:
Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 17 · Phase 4 28
First in 2001; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 256 is above the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 125 across the 66 interventional studies. Of the 58 that completed or were terminated, 13 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 67 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
41 studies in Gastroesophageal Reflux by Takeda: none open now, none under way, none of them phase 3. Of 39 finished, 22 (56%) have results posted.
Among the 41 studies in Gastroesophageal Reflux by Takeda, this one is the 18th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2016, is one of 7 in phase 2, and was the 38th registered.
Takeda’s Gastroesophageal Reflux studies by the year they started, since 2000.
1 of the studies testing esomeprazole in Gastroesophageal Reflux that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06953986Asian Institute of Gastroenterology, IndiaA Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks | 2026-11-20 |
Add it to your calendar (.ics) → With an account.
Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, from their registry updates:
Among Takeda’s 41 in Gastroesophageal Reflux:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effect of vonoprazan compared to esomeprazole for preventing heartburn symptoms over a 4-week treatment period in participants who have a partial response to treatment with esomeprazole.
The drug being tested in this study is called vonoprazan. Vonoprazan is being tested to treat people who have symptomatic gastroesophageal reflux disease (GERD) with a partial response to treatment with a high dose of esomeprazole. This study will look at improvement in heartburn symptoms in participants who take vonoprazan compared to esomeprazole.
The study will enroll approximately 213 patients. All participants will receive esomeprazole or esomeprazole placebo-matching capsules (this is a capsule that looks like esomeprazole but has no active ingredient) during a 7-week run-in period. Participants will then be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):
All participants will be asked to take one capsule at the same time each day throughout the study. All participants will be asked to record heartburn symptoms in a diary every morning upon waking and every evening before going to sleep.
This multi-center trial will be conducted in Europe. The overall time to participate in this study is 12 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone 1 week after the last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by esomeprazole 40 mg, over encapsulated tablets, orally, once daily for 4 weeks during the active treatment period.
Drug: Vonoprazan · Drug: Esomeprazole · Drug: Esomeprazole Placebo
Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 20 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the treatment period.
Drug: Vonoprazan · Drug: Esomeprazole · Drug: Esomeprazole Placebo
Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 40 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the active treatment period.
Drug: Esomeprazole · Drug: Esomeprazole Placebo
Vonoprazan over-encapsulated capsules
Also known as: TAK-438
Esomeprazole over-encapsulated tablets
Esomeprazole placebo-matching capsules
Percentage of Heartburn-Free 24-Hour Periods (Day and Night) During 4 Weeks of Treatment
Participants used the Reflux Symptom Questionnaire Electronic Diary (RESQ-eD) every morning upon waking and every evening before going to sleep to document the presence of daytime and nighttime heartburn and regurgitation. The percentage of heartburn-free (HBF) 24-hour periods was calculated for each participant using the following formula: (total 24-hour periods that are heartburn free / total 24-hour periods for which both a daytime and nighttime result is marked) x 100%.
Time frame: 4 Weeks
Percentage of Participants With ≥1 Sustained Resolution of Heartburn During the 4-Week Treatment Period
≥1 sustained resolution of heartburn is defined as ≥7 consecutive days without both daytime and nighttime heartburn anytime during the 4-week treatment period. Daytime and nighttime heartburn were documented by all participants using the Reflux Symptom Questionnaire Electronic Diary (RESQ-eD).
Time frame: 4 Weeks
Participants took part in the study at 33 investigative sites in Belgium, Bulgaria, Czech Republic, Estonia, Poland and United Kingdom from 14 July 2016 to 12 October 2018.
| Milestone | Esomeprazole 40 mg | Vonoprazan 20 mg | Vonoprazan 40 mg |
|---|---|---|---|
| Started | 86 | 85 | 85 |
| Completed | 82 | 84 | 82 |
| Not completed | 4 | 1 | 3 |
| Withdrew: Adverse event | 0 | 0 | 2 |
| Withdrew: Significant protocol deviation | 2 | 0 | 1 |
| Withdrew: Voluntary withdrawal | 2 | 1 | 0 |
Participants used the Reflux Symptom Questionnaire Electronic Diary (RESQ-eD) every morning upon waking and every evening before going to sleep to document the presence of daytime and nighttime heartburn and regurgitation. The percentage of heartburn-free (HBF) 24-hour periods was calculated for each participant using the following formula: (total 24-hour periods that are heartburn free / total 24-hour periods for which both a daytime and nighttime result is marked) x 100%.
| percentage of HBF 24-hour periods | Esomeprazole 40 mg | Vonoprazan 20 mg | Vonoprazan 40 mg |
|---|---|---|---|
| Percentage of Heartburn-Free 24-Hour Periods (Day and Night) During 4 Weeks of Treatment | 36.54 ± 35.570 | 36.69 ± 33.420 | 38.43 ± 34.793 |
≥1 sustained resolution of heartburn is defined as ≥7 consecutive days without both daytime and nighttime heartburn anytime during the 4-week treatment period. Daytime and nighttime heartburn were documented by all participants using the Reflux Symptom Questionnaire Electronic Diary (RESQ-eD).
| percentage of participants | Esomeprazole 40 mg | Vonoprazan 20 mg | Vonoprazan 40 mg |
|---|---|---|---|
| Percentage of Participants With ≥1 Sustained Resolution of Heartburn During the 4-Week Treatment Period | 32.6 | 30.6 | 31.8 |
Collected over Up to 5 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Esomeprazole 40 mg | 0/86 (0%) | 1/86 (1.2%) | 1/86 (1.2%) |
| Vonoprazan 20 mg | 0/85 (0%) | 0/85 (0%) | 0/85 (0%) |
| Vonoprazan 40 mg | 0/85 (0%) | 0/85 (0%) | 6/85 (7.1%) |
| Event | Esomeprazole 40 mg | Vonoprazan 20 mg | Vonoprazan 40 mg |
|---|---|---|---|
| Ischaemic strokeNervous system disorders | 1/86 | 0/85 | 0/85 |
| Event | Esomeprazole 40 mg | Vonoprazan 20 mg | Vonoprazan 40 mg |
|---|---|---|---|
| HypothyroidismEndocrine disorders | 0/86 | 0/85 | 3/85 |
| FlatulenceGastrointestinal disorders | 1/86 | 0/85 | 2/85 |
| Urinary tract infectionInfections and infestations | 0/86 | 0/85 | 2/85 |
The randomized set included all participants who were randomized into the study, regardless of whether they received any dose of the study drug.
| Age, Continuous(years) | Esomeprazole 40 mg | Vonoprazan 20 mg | Vonoprazan 40 mg | Total |
|---|---|---|---|---|
| Mean | 53.9 ± 13.94 | 52.0 ± 14.67 | 51.8 ± 14.09 | 52.6 ± 14.21 |
| Sex: Female, Male(Participants) | Esomeprazole 40 mg | Vonoprazan 20 mg | Vonoprazan 40 mg | Total |
|---|---|---|---|---|
| Female | 48 | 53 | 51 | 152 |
| Male | 38 | 32 | 34 | 104 |
| Race (NIH/OMB)(Participants) | Esomeprazole 40 mg | Vonoprazan 20 mg | Vonoprazan 40 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 0 | 1 | 0 | 1 |
| White | 86 | 84 | 83 | 253 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Esomeprazole 40 mg | Vonoprazan 20 mg | Vonoprazan 40 mg | Total |
|---|---|---|---|---|
| Belgium | 0 | 1 | 0 | 1 |
| Bulgaria | 61 | 55 | 61 | 177 |
| Czech Republic | 14 | 16 | 10 | 40 |
| Estonia | 2 | 5 | 4 | 11 |
| Poland | 8 | 7 | 7 | 22 |
| United Kingdom | 1 | 1 | 3 | 5 |
| Smoking Status(Participants) | Esomeprazole 40 mg | Vonoprazan 20 mg | Vonoprazan 40 mg | Total |
|---|---|---|---|---|
| Participant has never smoked | 50 | 53 | 53 | 156 |
| Participant is a current smoker | 21 | 23 | 22 | 66 |
| Participant is an ex-smoker | 15 | 9 | 10 | 34 |
| Alcohol Classification(Participants) | Esomeprazole 40 mg | Vonoprazan 20 mg | Vonoprazan 40 mg | Total |
|---|---|---|---|---|
| Participant has never drunk | 57 | 49 | 54 | 160 |
| Participant is a current drinker | 27 | 33 | 30 | 90 |
| Participant is an ex-drinker | 2 | 3 | 1 | 6 |
| Alcohol Use(Participants) | Esomeprazole 40 mg | Vonoprazan 20 mg | Vonoprazan 40 mg | Total |
|---|---|---|---|---|
| Less than 21 units of alcohol per week | 27 | 33 | 30 | 90 |
| Missing | 59 | 52 | 55 | 166 |
| Caffeine Consumption(Participants) | Esomeprazole 40 mg | Vonoprazan 20 mg | Vonoprazan 40 mg | Total |
|---|---|---|---|---|
| Yes | 60 | 67 | 68 | 195 |
| No | 26 | 18 | 17 | 61 |
9 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Jul 2016 to primary completion in Oct 2018, 26 months.
Results were first posted in Feb 2020, 1 year 4 months after primary completion.
Of 14 phase 2 interventional studies under Gastroesophageal Reflux, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 26 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esomeprazole